Drug intelligence / Profile preview

CAV-044

Development stage: Preclinical
Lead developer: Cavalry Biosciences
Modality: Recombinant Proteins and Enzymes

Overview

CAV-044 is a discovery-stage therapeutic candidate being developed by Cavalry Biosciences for the treatment of peripheral neuropathies, including Charcot-Marie-Tooth (CMT) disease. The program utilizes Cavalry's proprietary delivery platform, which is designed to transport therapeutic proteins directly to the peripheral nervous system. By targeting the peripheral nerves, CAV-044 aims to address the underlying pathophysiology of nerve damage and dysfunction in patients with hereditary and acquired neuropathies.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on CAV-044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAV-044.

Explore the full profile